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The next-generation sequencing revolution has substantially increased our understanding of the mutated genes
that underlie complex neurodevelopmental disease. Exome sequencing has enabled us to estimate the number of
genes involved in the etiology of neurodevelopmental disease, whereas targeted sequencing approaches have
provided the means for quick and cost-effective sequencing of thousands of patient samples to assess the
significance of individual genes. By leveraging such technologies and clinical exome sequencing, a genotype-first
approach has emerged in which patients with a common genotype are first identified and then clinically
reassessed as a group. This approach has proven a powerful methodology for refining disease subtypes. We
propose that the molecular characterization of these genetic subtypes has important implications for diagnostics
and also for future drug development. Classifying patients into subgroups with a common genetic etiology and
applying treatments tailored to the specific molecular defect they carry is likely to improve management of
neurodevelopmental disease in the future.A shift to a genotype-first approach
Neurodevelopmental disorders (NDs) refer to a complex
collection of phenotypes that encompass clinically
recognizable disorders such as autism spectrum disor-
ders (ASD), intellectual disability (ID), epilepsy and
schizophrenia. The diagnosis of NDs has classically
fallen within the clinical realm. The diagnosis of epilepsy
is somewhat quantitative, with the frequency, onset and
family history of seizure events being considered for
classification [1], whereas the diagnosis of ASD, ID and
schizophrenia is historically more complex. The Diag-
nostic and Statistical Manual of Mental Disorders (DSM,
currently DSM-5) is recognized by the US healthcare
system as a standard battery of diagnostic criteria for
classifying mental disorders. These criteria recognize pa-
tients with ASD as those with primarily communication
deficits, which can be measured by several standardized
tests (e.g., ADOS, ADI-R and BAPQ). In addition to
intelligence quotient (IQ) testing, ID is classified by the
DSM-5 as involving adaptive functioning impairments in
the conceptual, social and practical skills domains. Indi-
viduals diagnosed with schizophrenia must present with* Correspondence: eee@gs.washington.edu
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delusions, hallucinations, disorganized speech and be-
havior, and social/occupational dysfunction [2].
Earlier versions of the DSM included phenotypic sub-
types for many mental health disorders that have since
been eliminated owing to inconsistent diagnoses between
clinicians. However, the study of these disorders, ASD and
ID in particular, has shown that disease subtypes do exist
(such as high-functioning ASD, previously Asperger syn-
drome) [3]. Twin studies of ASD, epilepsy and schizophre-
nia showed that NDs have a strong genetic component
(heritability [h2] = 40–80 % [4–6], h2 = 70–88 % [7], and
h2 = 64–81 % [8, 9], respectively). The existence of exten-
sive comorbidity among ND diagnoses has long been rec-
ognized; for example, 28 % of individuals who have ID
also present with ASD [10], whereas 26 % present with
epilepsy [11] and 3.7–5.2 % with schizophrenia [12].
Phenotypic overlap between NDs led to an early hy-
pothesis that common risk genes underlie multiple
NDs and, furthermore, that genetic characterization
could be a useful diagnostic tool for ND identification
and treatment [13].
Studies of copy number variation and whole-exome or
whole-genome sequencing (WES and WGS, respectively)
of families have highlighted the importance of rare, de
novo gene-disruptive mutations in the genetic etiologycle is distributed under the terms of the Creative Commons Attribution 4.0
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copy number variant, biochemical pathway or even the
same gene as an underlying factor of seemingly diverse
clinical and etiological outcomes (Table 1). One classic
example of this genetic overlap is a microdeletion in
chromosome 15q11.3, which has been associated with
multiple NDs (ASD, ID, epilepsy and schizophrenia)
[14]. At the single-gene level, exome sequencing studies
have highlighted that specific loci, such as SYNGAP1,
ARID1B and ADNP, are likely to contribute to both ASD
and ID, whereas mutations in genes such as STXBP1
and WDR45 might contribute to ID and epilepsy but not
ASD (Table 1). Recognition of this genetic overlap and
the subtlety of the clinical diagnoses of NDs have led to
the development of a so-called genotype-first approach,Table 1 Top de novo genes associated with ND risk
Gene ASDb ID/DDc EPd SZe Total cases
SYNGAP1a 7 9 0 0 16
SCN2Aa 6 7 0 1 14
ARID1Ba 5 11 0 0 16
ANKRD11a 2 8 0 0 10
CHD8a 12 0 0 1 13
ADNPa 5 4 0 0 9
DYRK1Aa 5 3 0 0 8
CTNNB1a 1 6 0 0 7
CHD2a 5 2 1 0 8
STXBP1 0 5 1 0 6
POGZ 3 2 0 1 6
MED13L 2 4 0 0 6
TRIP12 2 2 0 0 4
KMT2A 2 4 0 0 6
EP300 1 4 0 0 5
GRIN2B 3 1 0 0 4
DDX3Xa 1 2 0 0 3
SUV420H1 3 0 0 0 3
WDR45 0 2 1 0 3
CHAMP1a 0 3 0 0 3
SCN1Aa 0 0 4 0 4
WACa 2 2 0 0 4
AHDC1a 1 2 0 0 3
SATB2 0 3 0 0 3
All counts represent de novo mutations that are likely to be gene-disruptive, includ
genotype-first approaches. b5001–5922 individuals with ASD were screened depend
individuals with ID/DD were screened. ID/DD data have been previously published
published [32, 33]. e785 individuals with SZ were screened. SZ data have been prev
from the ExAC database. The disruptive mutations counted here represent unaffect
neuropsychiatric disorders [37]. These data were used to calculate the Fisher’s exact
in cases and controls. gPathway annotations determined using the Database for Annot
ASD Autism spectrum disorders, C Chromatin remodeling, CI Confidence interval, D
ID Intellectual disability, K Kinase, OR Odds ratio, R Replication, S Synapse function
W Wnt/β-catenin signalingin which patients with a common genotype (i.e., a dis-
ruptive variation in the same gene) are collected for deep
clinical phenotyping to define the specific disease attri-
butes associated with each candidate ND risk gene [15].
This approach contrasts with phenotype-driven ap-
proaches, in which patients are collected on the basis of
a shared clinical presentation and used to identify candi-
date risk genes post hoc.
The goal of this Opinion is to review advances in the
discovery of candidate genes based on next-generation
sequencing of patients and the impact of these advances
on refining specific subtypes of ND. Linking genotypes
to deep clinical phenotypes (including information ob-
tained through application of best-practice DSM-5
criteria, clinical dysmorphology assessment, analysis ofControl countsf p value OR (95 % CI) Pathwayg
1 1.45E-12 88.0 (13.7–3613.0) S
1 1.34E-11 86.7 (13.2–3587.4) S
5 9.29E-10 17.6 (6.2–61.5) C, T, W
1 2.63E-08 61.9 (8.8–2644.0) D
4 3.52E-08 17.9 (5.5–75.2) C, T, W
2 1.99E-06 24.7 (5.1–234.2) T
1 2.46E-06 44.0 (5.9–1929.7) K, D
1 1.42E-05 38.5 (4.9–1716.8) T, W
3 3.36E-05 14.7 (3.5–85.7) C, T
1 8.12E-05 32.9 (4.0–1503.0) S
2 1.58E-04 18.5 (3.3–187.6) R
2 2.82E-04 16.5 (2.9–166.8) T, W
0 5.63E-04 ∞ (3.6–∞) U
4 9.24E-04 9.3 (2.2–44.7) C
3 2.03E-03 10.3 (2.0–66.5) C, T, W
1 2.47E-03 22.0 (2.2-1075.1) S
0 2.70E-03 ∞ (2.6–∞) T, W
0 2.70E-03 ∞ (2.6–∞) C, T
0 2.70E-03 ∞ (2.6–∞) A
0 3.66E-03 ∞ (2.3–∞) R
2 6.50E-03 11.0 (1.6–121.5) S
2 6.50E-03 11.0 (1.6–121.5) C, T
1 9.68E-03 18.5 (1.5–967.5) Db
1 9.68E-03 18.5 (1.5–967.5) C, T
ing frameshift, splice and nonsense mutations aGene also identified through
ing on the gene. ASD data have been previously published [19, 23–28]. c1284
[29–31]. d274 individuals with EP were screened. EP data have been previously
iously published [34–36]. fData from 45,376 control individuals were obtained
ed population control individuals and individuals with diseases other than
test p value. Only disruptive (frameshift, splice, nonsense) variants were scored
ation, Visualization and Integrated Discovery (DAVID) v6.7 [57, 58]. A Autophagy,
Broad development, Db DNA binding, DD Developmental delay, EP Epilepsy,
, SZ Schizophrenia, T Gene transcription, U E3 ubiquitin-protein ligase,
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important insight into ND risk gene models [16–18].
We propose that grouping patients on the basis of a
shared genetic etiology is a critical first step in tailoring
improved therapeutics to a defined subset of patients.
Gene discovery and phenotypic refinement
The affordable application of next-generation sequen-
cing in the clinical and research arenas has rapidly in-
creased our understanding of the genetic variation that
underlies NDs. Exome and targeted sequencing studies
of patients with ND have revealed dozens of new genes
emerging as high-risk candidate loci in recent years
(Table 2). WES sequencing of patients with ASD led to
estimates that 500–1000 genes contribute to disease eti-
ology [19], whereas in ID this number is greater than
1000 [20]. Epilepsy and schizophrenia are thought to be
less genetically heterogeneous, involving approximately
500 [21] and 600 [22] genes, respectively. Although asso-
ciations between certain gene variants and ND risk have
been consistently replicated (such as de novo disruptive
mutations in CHD8, ADNP and DYRK1A [19] among
ASD and ID simplex families), hundreds of ND risk
genes remain undiscovered or have not been associated
with NDs with sufficient statistical significance owing
to ultra-low mutation frequencies in the patient
population.
We combined the results of multiple published WES,
WGS and targeted sequencing studies including 5001–
5922 individuals with ASD (single gene denominators
varied owing to the variety of WES, WGS and targeted
sequencing approaches used) [19, 23–28], 1284 individ-
uals with ID [29–31], 274 individuals with epilepsy [32,
33] and 785 individuals with schizophrenia [34–36] to
look for genetic overlap between these NDs. Using this
large dataset (over 7000 individuals/families), we identi-
fied the top 25 genes that show an excess of disruptive
(frameshift, splice, nonsense) gene mutations in disease
cases when these individuals are compared with 45,376
controls drawn from the ExAC database [37], where
neuropsychiatric cases were masked before analysis
(Table 1). Although the number of individuals repre-
sented in each disease study differs and several genes
reach only nominal significance, the identified genes
clearly converge on common biochemical and neurode-
velopmental pathways, such as synaptic function, chroma-
tin remodeling, gene transcription and Wnt/β-catenin
signaling. Importantly, significance thresholds are likely to
be highly conservative, as the ND studies that were in-
cluded in the analysis only considered confirmed de novo
events, whereas the ExAC database variants have not been
filtered for population frequency and inheritance status is
unknown. Using our large dataset of de novo mutations
associated with ND we can apply a recurrent de novosimulation model which considers the size and evolution-
ary conservation of individual genes to calculate the likeli-
hood of observing a number of de novo mutations in any
given ND-associated gene [23]. In some cases we find that
genes that were not statistically significant for overall
disruptive mutational burden after Bonferroni correction
(p < 10-6) of the Fisher’s exact test p value are indeed sig-
nificant for recurrent de novo mutation burden — such as
GRIN2B, which has a de novo p value of 0.001 after cor-
rection. Therefore, although some genes (e.g., GRIN2B)
reach only nominal significance for an overall increased
burden in disruptive mutations in ND cases compared
with unaffected controls, based on a de novo model they
may prove to be bona fide ND risk genes.
The discovery of recurrently mutated genes has been
used to successfully identify additional patients with disrup-
tive mutations in these risk genes who, when collectively
phenotyped, define new syndromic and sub-syndromic
forms of ND [16–18]. These efforts have proceeded in
parallel with the coordination of clinical exome sequen-
cing of patients, which has led to the identification of
dozens of individuals with the same type of rare molecular
defect (Table 2). This coordination led to the emergence
of refined patient checklists that enable a systematic re-
assessment of pediatric, neuroimaging, neurobehavioral
and morphological features [15]. Such genotype–pheno-
type studies have shown that individuals sharing a genetic
etiology have more features in common than those they
share with the general ND population. These observations
have led to the description of both genetic and clinical
subtypes of ND, some of which may be considered syn-
dromic by clinicians.
Many of the top ND risk genes identified in our ana-
lysis are correlated with an observable phenotype that
may have been predicted based on our analysis (Tables 1
and 2). For example, CHD8 is an ASD-associated gene
linked with macrocephaly and gastrointestinal dysfunc-
tion [16], whereas ADNP mutations are associated with
ASD and the complete loss of expressive language [17].
Some genes seem to be predominantly associated with
ID (e.g., ARID1B, ANKRD11, CTNNB1, STXBP1 and
CHAMP1). SCN1A mutations have been primarily ob-
served in epilepsy [38]. Other genes are strongly associ-
ated with epilepsy and ID (e.g., CHD2 and DYRK1A),
often with very specific clinical manifestations (e.g.,
microcephaly and late-onset epilepsy in the case of pa-
tients with DYRK1A variants [18]. The potential contri-
bution of some of these ND genes (e.g., SCN2A, CHD8
and POGZ; Table 1) to adult neuropsychiatric diseases,
such as schizophrenia, is intriguing, although statistical
significance supporting these associations is still lacking.
The existence of such associations would suggest that
mutations in these genes have broad phenotypic effects
or variable expressivity that manifests as ND at different
Table 2 Genes linked to NDs identified through genotype-first approaches
Gene Locus Phenotype References
ADNP 20q13.13 ASD, ID, loss of expressive language, facial dysmorphisms [17]
AHDC1 1p35.3 ID/DD, hypotonia, mild dysmorphic facial features, sleep apnea [59]
ANKRD11 16q24.3 KGB syndrome: macrodontia of central upper incisors, dental anomalies, facial dysmorphism,
ASD, hyperactivity, hearing loss, heart defects
[60, 61]
ARID1A 1p36.11 Coffin–Siris syndrome with sucking/feeding difficulties, distinct faces including some facial coarseness
with short nose, gastrointestinal complications, some hearing and visual impairments, prone to infection,
hypotonia, structural CNS abnormalities, mild to severe ID/DD, behavioral abnormalities
[62, 63]
ARID1B 6q25.3 Highly variable Coffin–Siris syndrome with hypoplasia of the corpus callosum, hearing problems [62, 64]
ARID2 12q12 ID/DD, ADHD, short stature, dysmorphic facial features, Wormian bones [65]
AUTS2 7q11.22 ID, ASD, short stature, microcephaly, cerebral palsy, facial dysmorphism [66]
BRWD3 Xq21.1 Mild to moderate ID, speech delay, behavioral disturbances, macrocephaly, dysmorphic facial features,
skeletal symptoms
[67]
CHAMP1 13q34 ID, speech impairment, motor DD, muscular hypotonia, dysmorphic features [68]
CHD2 15q26.1 Archetypal generalized photosensitive epilepsy syndrome, eyelid myoclonia with absences, ID, ± ASD [38, 69–71]
CHD8 14q11.2 ASD, macrocephaly, distinct faces, gastrointestinal complaint, sleep disturbance [16]
CTNNB1 3p22.1 ID, microcephaly, limited speech and progressive spasticity [72, 73]
CUL4B Xq24 X-linked ID, cerebral malformations, seizures, tremors, gait abnormalities, behavioral problems,
macrocephaly, short stature, obesity, hypogonadotropic hypogonadism, variable dysmorphic features
[74]
DDX3X Xp11.4 ID, hypotonia, movements disorders, behavior problems, corpus callosum hypoplasia, EP [53]
DEAF1 11p15.5 Severe ID, severely affected speech development, behavioral problems [75]
DYNC1H1 14q32.31 Severe ID, neuronal migration defects, broad phenotypic spectrum [76]
DYRK1A 21q22.13 DD, ASD, microcephaly, late-onset EP, severe anxiety [18]
GATAD2B 1q21.3 Severe ID, childhood hypotonia, limited speech, tubular nose with broad nasal tip, short philtrum,
sparse hair and strabismus
[77]
GRIN2A 16p13.2 Epilepsy–aphasia spectrum disorders [78]
HDAC8 Xq13.1 ID, behavioral problems (including ASD in some patients), delayed anterior fontanelle closure, ocular
hypertelorism, hooding of the eyelids, broad nose and dental anomalies
[79]
HIVEP2 6q24.2 ID, structural brain anomalies, hypotonia, mild dysmorphic features [80]
KCNH1 1q32.2 Severe ID, neonatal hypotonia, hypertelorism, broad nasal tip, wide mouth, nail aplasia or hypoplasia,
proximal implanted and long thumb and long great toes
[81]
KCNT1 9q34.3 Highly pleiotropic, including nocturnal frontal lobe EP, malignant migrating focal seizures of infancy,
Ohtahara syndrome, multifocal EP, cardiac disturbances
[82]
KDM5C Xp11.22 X-linked ID [83]
KIAA2022 Xq13.3 X-linked ID, ASD features, strabismus [84]
KIF1A 2q37.3 Cognitive impairment, variable cerebellar atrophy, spastic paraparesis, optic nerve atrophy,
peripheral neuropathy, EP
[85]
KIF4A Xq13.1 ID, EP [86]
KIF5C 2q23.1 Severe ID, EP, microcephaly, cortical malformation [86]
MAN1B1 9q34.3 ID, delayed motor and speech development, obesity, macrocephaly [87]
MLL2
(KMT2D)
12q13.12 Severe form of Kabuki syndrome with distinct facial features (large dysplastic ears, arched eyebrows with
sparse lateral third, blue sclerae, flat nasal tip with a broad nasal root, a thin upper lip and a full lower lip)
[88]
MYT1L 2p25.3 Syndromic ID and/or central obesity [89]
NRXN1 2p16.3 Predisposition for idiopathic generalized EP syndromes [90]
PGAP1 2q33.1 ID, cerebral visual impairment [91]
PHF21A 11p11.2 Potocki–Shaffer syndrome associated with ID and craniofacial anomalies [92]
PPP2R1A 19q13.41 ID, hypotonia, EP, frontal bossing, mild hypertelorism, downslanting palpebral fissures [93]
PPP2R5D 6p21.1 ID, ASD, macrocephaly, hypotonia, seizures, dysmorphic features [93, 94]
SCN1A 2q24.3 EP with febrile seizures plus generalized epilepsy with febrile seizure plus (GEFS+), epilepsy–aphasia [38]
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SCN2A 2q24.3 ID/DD, seizure disorders (epileptic encephalopathy); previously implicated in ASD and SZ [38, 95, 96]
SCN8A 12q13.13 Early-infantile epileptic encephalopathy type 13, ± ID, hypotonia, movement disorders [38, 97, 98]
SETBP1 18q12.3 ID, loss of expression language [99]
SETD5 3p25.3 ID, facial dysmorphism [100]
SLC6A1 3p25.3 Spontaneous spike-wave discharges associated with epileptic encephalopathy [101]
SMARCA4 19p13.2 Coffin–Siris syndrome with moderately coarse craniofacial features and behavioral abnormalities [62, 63]
SMARCB1 22q11.23 Coffin–Siris syndrome with severe neurodevelopmental deficiencies, including severe ID, seizures,
CNS structural abnormalities, no expressive words, scoliosis
[62, 63]
SMARCE1 17q21.2 Coffin–Siris syndrome with severe to moderate ID and a wide spectrum of manifestations [63]
SMC3 10q25.2 Cornelia de Lange syndrome with postnatal microcephaly, moderately distinctive craniofacial appearance,
mild prenatal growth retardation that worsens in childhood, some congenital heart defects, absence of
limb deficiencies
[102]
SRCAP 16p11.2 Floating–Harbor syndrome: short stature with delayed bone age, deficits in expressive language, distinctive faces [103]
SYNGAP1 6p21.32 Multiple seizure types, early DD, regression, ID [38]
USP9X Xp11.4 X-linked ID [104]
WAC 10p11.23 ID/DD, hypotonia, behavioral problems, eye abnormalities, constipation, feeding difficulties, seizures, sleep
problems, dysmorphic features
[105]
ZMYND11 10p15.3 ID, ASD, aggression, complex neuropsychiatric features [99]
ADHD Attention deficit hyperactivity disorder, ASD Autism spectrum disorders, CNS Central nervous system, DD Developmental delay, EP Epilepsy, ID Intellectual
disability, SZ Schizophrenia
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families in which gene-disruptive mutations in these
genes are segregated in order to explore phenotypic dif-
ferences among the familial carriers.
Molecular pathways and therapeutic potential
Beyond genetic subtypes, network-based approaches that
more globally predict the effects of ND risk genes on
molecular pathways have repeatedly shown an enrich-
ment for synapse function and gene transcription/chro-
matin remodeling [19, 39]. Although these pathways
remain the most statistically significant pathways found
among ND datasets, other pathways have been identi-
fied, including interaction with SNARE proteins and ves-
icular transport pathways in epilepsy (p < 0.03) and
FMRP targets in ASD, ID and epilepsy (p < 0.00001)
[39]. Given the extensive locus heterogeneity of these
diseases, pathway-defined ‘molecular subtypes’ are likely
to become the ultimate target for behavioral and
pharmacological therapeutics.
Each of these large functional networks can be further
subdivided into smaller pathways, such as long-term po-
tentiation, calcium signaling, postsynaptic density and
synapse structure in the case of synaptic function, in
which enrichment is driven by signals from de novo mu-
tations in genes such as SYNGAP1, SCN2A, STXBP1,
GRIN2B and SCN1A (Table 1). SCN2A and SCN1A are
members of the same gene family of voltage-gated so-
dium channels that are responsible for the generation
and propagation of action potentials and have been asso-
ciated with seizure phenotypes in animal models [38].Although SCN1A de novo mutations seem to be specific
to epilepsy [38], we observe SCN2A de novo mutations
in both ASD and ID (Table 1), which suggests that long-
term potentiation has a role in multiple forms of ND. It
is important to note, however, that we are classifying
mutations using the primary clinical diagnosis under
which each patient’s cohort was originally ascertained.
As a large phenotypic overlap exists between NDs, we
could reasonably hypothesize, for example, that patients
with ASD or ID and an SCN2A mutation could also
manifest with seizure phenotypes.
An enrichment for synapse function in ND has been
observed primarily in a subset of patients with ID, epi-
lepsy and schizophrenia [39]. Many antipsychotic and
psychotropic compounds have been developed to modu-
late synaptic function to treat comorbid conditions
(hyperactivity, depression, anxiety, aggression and sei-
zures) often associated with NDs. These medications
may be used more effectively when applied to patients
with a molecular perturbation in the relevant gene or
pathway. For example, benzodiazepines (e.g., clonaze-
pam) are a class of drugs that increase GABAA receptor
activity and thus contribute to the inhibition of action
potentials in the central nervous system, which are often
overactive in seizure conditions [40]. Efforts are cur-
rently underway to specifically tailor benzodiazepines to
treat patients with mutations in SCN2A and SCN1A [41,
42] (Dr. Raphael Bernier, personal communication).
Clemizole, a compound approved by the US Food and
Drug Administration, has been shown to mitigate some
of the convulsive behavior of Scn1a mutant zebrafish
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ment of other similar sodium-channel-inhibiting com-
pounds, including GS967 [44].
Studies of simplex ASD and ID families have
highlighted an enrichment for gene-disruptive mutations
in transcription and chromatin remodeling pathways
(e.g., SWI/SNF complex, Wnt/β-catenin and mTOR)
[19, 39, 45]. Wnt/β-catenin and mTOR pathways are in-
volved in gene transcription, cell growth, migration and
patterning during embryonic development [46, 47].
These pathways are closely linked to the SWI/SNF nu-
cleosome remodeling complex, which is involved in the
regulation of gene expression and is thought to have a
role in neural specification [48]. Understanding the mo-
lecular biology of these pathways may reveal additional
therapeutic targets. ADNP, for example, is a transcription
factor that interacts directly with the SWI/SNF complex.
Davunetide, a derivative octapeptide of ADNP, has been
shown to ameliorate some of the cognitive deficits in
animal models with ADNP mutations, which is a prom-
ising line of therapeutic research for ADNP patients with
similar defects [49]. Some ND-associated genes (Table 1)
are simultaneously involved in chromatin remodeling
and transcription, such as ARID1B [50] and CHD8 [51],
which have been linked to the SWI/SNF and Wnt/β-ca-
tenin signaling pathways [16, 50] (Table 1) and are
known to be important for proliferation of neural pre-
cursors [23, 39, 52].The study of genetic subtypes of ND
associated with the Wnt/β-catenin pathway — specifically
DDX3X and CHD8— suggests that mutations in this path-
way are important in the very early stages of development
[16, 53]. Importantly, mutations in DDX3X account for a
large percentage of unexplained ID in female individuals
(1–3 %) [53], which was overlooked in studies of ASD
alone [54] (Table 1). The Wnt/β-catenin pathway is com-
monly dysregulated in cancer; over 40 compounds have
been shown to modulate Wnt/β-catenin pathway activity
in model systems or in vivo that might be considered for
use in specific genetic subtypes of ND in the future [55].
Mutations in the mTOR pathway involving genes such
as TSC and PTEN have also been implicated in tumori-
genesis and ND owing to their role in transcription and
cell growth [47]. Rapalogues, including sirolimus (rapa-
mycin) and everolimus, which inhibit TORC1 and are
commonly used to treat cancer, are currently under in-
vestigation to assess whether they can improve ASD-
related symptoms in patients with TSC mutations [56].
Similar disease-modifying therapies might be useful to
treat patients with other genetic subtypes of ND in
which mTOR function is abrogated. However, the use of
drugs targeting both Wnt/β-catenin and mTOR path-
ways will need to be carefully considered and fine-tuned
for use in NDs to avoid adverse side effects. Although
killing healthy cells in adults is an acceptable consequenceof cancer treatment, this is not the case during pediatric
brain development.
Conclusions
The success of the genotype-first approach for subtyping
NDs can be primarily attributed to technological ad-
vances that make WES and targeted sequencing fast and
cost-effective. ND candidate gene discovery can be maxi-
mized by combining many datasets from overlapping
conditions (e.g., ASD, ID, epilepsy and schizophrenia) to
(1) increase the genetic evidence supporting individual
ND risk gene models, (2) build stronger molecular inter-
action networks that implicate specific pathways in disease
biology and (3) assess the robustness of genotype–pheno-
type links. Beyond providing a potential genetic explan-
ation for disease to families, our understanding of the
biological pathways that are disrupted by specific variants
is leading to improved assessment of disease risk in fam-
ilies and to the prospect of tailored treatments for patients
with these debilitating diseases.
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